Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1983 1
1985 3
1986 4
1987 1
1988 1
1989 5
1990 3
1991 14
1992 6
1993 4
1994 8
1995 5
1996 6
1997 7
1998 4
1999 3
2000 5
2001 10
2002 10
2003 7
2004 10
2005 18
2006 20
2007 23
2008 25
2009 25
2010 26
2011 19
2012 11
2013 14
2014 19
2015 18
2016 20
2017 29
2018 22
2019 27
2020 19
2021 7
2022 14
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Kendler DL, et al. Among authors: geusens p. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9. Lancet. 2018. PMID: 29129436 Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Fracture liaison programs.
Geusens P, Bours SPG, Wyers CE, van den Bergh JP. Geusens P, et al. Best Pract Res Clin Rheumatol. 2019 Apr;33(2):278-289. doi: 10.1016/j.berh.2019.03.016. Epub 2019 May 16. Best Pract Res Clin Rheumatol. 2019. PMID: 31547983 Review.
Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute.
Carbone F, Van den Houte K, Besard L, Tack C, Arts J, Caenepeel P, Piessevaux H, Vandenberghe A, Matthys C, Biesiekierski J, Capiau L, Ceulemans S, Gernay O, Jones L, Maes S, Peetermans C, Raat W, Stubbe J, Van Boxstael R, Vandeput O, Van Steenbergen S, Van Oudenhove L, Vanuytsel T, Jones M, Tack J; DOMINO Study Collaborators; Domino Study Collaborators. Carbone F, et al. Gut. 2022 Nov;71(11):2226-2232. doi: 10.1136/gutjnl-2021-325821. Epub 2022 Apr 28. Gut. 2022. PMID: 35483886 Free PMC article. Clinical Trial.
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP. Shane E, et al. Among authors: geusens p. J Bone Miner Res. 2014 Jan;29(1):1-23. doi: 10.1002/jbmr.1998. Epub 2013 Oct 1. J Bone Miner Res. 2014. PMID: 23712442 Free article. Review.
Reply.
Saag KG, Geusens P, Lems WF. Saag KG, et al. Among authors: geusens p. Arthritis Rheumatol. 2019 Oct;71(10):1771-1772. doi: 10.1002/art.41013. Epub 2019 Sep 2. Arthritis Rheumatol. 2019. PMID: 31215773 No abstract available.
Inflammatory diseases and bone fragility.
Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Briot K, et al. Among authors: geusens p. Osteoporos Int. 2017 Dec;28(12):3301-3314. doi: 10.1007/s00198-017-4189-7. Epub 2017 Sep 15. Osteoporos Int. 2017. PMID: 28916915 Review.
434 results